Kronos Bio, Inc.

NASDAQ (USD): Kronos Bio, Inc. (KRON)

Last Price

0.851

Today's Change

-0.029 (3.29%)

Day's Change

0.84 - 0.895

Trading Volume

607,031

Overview

Market Cap

51 Million

Shares Outstanding

60 Million

Avg Volume

76,709

Avg Price (50 Days)

0.95

Avg Price (200 Days)

1.06

PE Ratio

-0.49

EPS

-1.74

Earnings Announcement

11-Nov-2024

Previous Close

0.88

Open

0.88

Day's Range

0.8402 - 0.895

Year Range

0.69 - 1.6

Trading Volume

607,031

Price Change Highlight

1 Day Change

-3.31%

5 Day Change

-2.22%

1 Month Change

-7.50%

3 Month Change

-13.74%

6 Month Change

-14.86%

Ytd Change

-29.08%

1 Year Change

13.47%

3 Year Change

-94.92%

5 Year Change

-96.86%

10 Year Change

-96.86%

Max Change

-96.86%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company planned registrational phase 3 clinical trial of ENTO in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations. It is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in San Mateo, California.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment